Small molecule · developed by Hutchmed
150 µCi HMPL-523 is a radiolabeled ([14C]) form of the small molecule HMPL-523, studied in a human mass balance trial in immune thrombocytopenia (ITP).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05781906 | Phase 1 | Imumune Thrombocytopenia(ITP) Human Mass Balance | Completed | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Imumune Thrombocytopenia(ITP) Human Mass Balance
Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →